Efgartigimod alfa-fcab

(Vyvgart®)

Efgartigimod alfa-fcab

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 20 mg/mL)
Drug ClassNeonatal Fc receptor blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyvgart (efgartigimod alfa-fcab) Prescribing Information.2022argenx BV, Zwijnaarde, Belgium

Systematic Reviews / Meta-Analyses